bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a831b3e2b964299a4855303bed4aa0a&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8378b1a98c40878bb3f8252fa8388b&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a827cbc3bf94482b3907872c0648994&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a842d3f6b6d440fa80086a2dff74dbd&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84ebb398c94ab1b8dc18f7bb0062e6&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a82a88d4b2c4a93adcb8efd601e4582&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84ac2e09ad4aa997a84e290fa653b8&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84e7f4a30d4c4d8f8cd93937c440f8&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a844f34d3e840c8abc734b79e0e10c1&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a82f581f0444855800209e21a019dce&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84dceee02c4a6db017a39a48fe1c15&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a82fb2306ef41b790bb234f7f9cf10b&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a8300ea4d9f430b9b1fc2021f311e3c&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a843d3bb4514c669cffd86505384bec&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a84f8dbf63743eaa24dad4ac88f7b5b&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
bing.com
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrencehttp://www.bing.com/news/apiclick.aspx&aid=&tid=6a83ae74312244a7a9ec9864b7c52dba&url=https%3a%2f%2fmedicalxpress.com%2fnews%2f2022-04-lab-egfr-inhibitors-rhabdomyosarcoma-recurrence.html&c=7763211995335802911&mkt=en-usRhabdomyosarcoma is a type of soft tissue cancer. Scientists at St. Jude Children's Research Hospital studied the population of cells that persists after therapy, causing rhabdomyosarcoma recurrence.Apr 27, 2022 9:45 AM
news.ycombinator.com
Ask HN: Finding a technical lead in Cambridge, MA?https://news.ycombinator.com/item?id=8675900Over the last several months, I have tested and validated a business opportunity in the legal space. Customers are very interested - 4 or the last 5 have asked to be part of a paid Beta as soon as possible. I'd like to get something workable into customers hands as soon as possible, but am hamstrung by my technical skills.I'm by background and skillset much more business than technically oriented. I know enough Python/Django to be dangerous and have built a working proof-of-concept / demo. However, I know when I'm at the limit of my capabilities, and to take it from POC to working product, would like to bring on someone to help buildout a real product.Some of the problems that need to be solved for (many of which I've been dealing with in one capacity or another): - web scraping. Done mostly with BeautifulSoup to date + lots of custom regexes. There are a lot of corner cases to deal with. - regularly scraping 10,000s of pages and watching for changes on those pages - entity and person Nov 30, 2014 3:42 AM
news.ycombinator.com
Ask HN: Where do you find things worth reading?https://news.ycombinator.com/item?id=49404106There’s more good writing and reporting available than ever, but I’m finding it harder to discover the stuff that’s actually worth reading.What are your goto sources for finding interesting things to read about your interests? Could be websites, newsletters, RSS feeds, blogs, Substacks, authors, apps, or anything else.A few I check regularly:- Hacker News- Rest of World: https://restofworld.org/- Substack: mostly following individual authors/publications rather than browsing the feedI’m especially interested in sources that have helped you discover writers or publications you wouldn’t have found otherwise.What do you read, and how did you find it?Aug 22, 2026 9:36 PM
tosynch.com
Show HN: Tosynch – reconnect with your friends and meet oftenhttps://tosynch.comI built this app to solve problem I had, and perhaps others too. I have been finding tough stay in touch with friends. Other than occasional hi/hellos, there is lack of meaningful interactions ongoing basis. Tosynch helps with connecting with existing friends, without calendar setup. It does one thing only and focuses on that. There is no hidden agenda of selling personal data for ads, nor any scheme around increasing likes. There is no discovery mechanism, and no public profiles. If we want to reduce our usage of phones and devices, we don't need another app to helps us constrained. We want to create more opportunities to meet people we already know. Tosynch helps increase those opportunities. It nudges after a chosen period, to reconnect and meet. Feedback appreciated.Aug 21, 2026 3:10 PM
france24.com
Hopes fade after Central African Republic gold mine collapse kills dozenshttps://www.france24.com/en/video/20260821-hopes-fade-after-central-african-republic-gold-mine-collapse-kills-dozensHopes of finding survivors at a collapsed gold mine in Central African Republic were fading Thursday, two days after a disaster that local officials and the Red Cross said killed more than 100 people, although the government put the death toll at 49. Thirty-five Central Africans, 13 Cameroonians and two Chadians died in the collapse, Mines Minister Rufin Benam Beltoungou told independent broadcaster Radio Ndeke Luka. His toll was significantly lower than figures provided by local officials, witnesses and relatives of victims, who have said more than 100 people died.Aug 21, 2026 11:31 AM
